Form 4: Klotho Director Boosts Stake, Acquires Options

Klotho Neurosciences Director and 10% Owner Samuel M. Zentman increased his beneficial ownership of common stock and acquired additional non-qualified stock options.

Summary

• Samuel M. Zentman, a Director and 10% Owner of Klotho Neurosciences, Inc. (KLTO), increased his beneficial ownership.
• Acquired 153,494 shares of common stock on August 5, 2025, as contingent merger consideration.
• Following this transaction, beneficial ownership of common stock stands at 736,440 shares, held indirectly through The Samuel Zentman 2012 Irrevocable Trust.
• Acquired 10,000 non-qualified stock options on August 7, 2025, with an exercise price of $0.41 per share.
• These options are fully vested and exercisable at any time, expiring on January 16, 2035.
• Total beneficial ownership of derivative securities (options) is now 40,000.

Sentiment

Score: 8

Explanation: The filing indicates a significant increase in beneficial ownership by a key insider (Director and 10% owner) through both common stock from a merger contingency and new stock options. This demonstrates strong confidence from management in the company's future prospects and value, which is a very positive signal for investors.

Positives

• A Director and 10% owner increasing their beneficial ownership signals confidence in the company's future prospects.
• The acquisition of 153,494 shares as contingent merger consideration indicates the fulfillment of prior merger terms, potentially a positive milestone.
• The acquisition of 10,000 fully vested stock options at an exercise price of $0.41 suggests a belief in the stock's potential to rise above this price.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide broader industry context or trends. It pertains specifically to Klotho Neurosciences, Inc.

Related Party Transactions

• The 736,440 shares of common stock beneficially owned by the reporting person are held indirectly through The Samuel Zentman 2012 Irrevocable Trust.

Stakeholder Impact

• Shareholders: The increase in beneficial ownership by a Director and 10% owner may be viewed positively, signaling management's confidence and potentially influencing investor sentiment.

Key Dates

Recommendation

The acquisition of additional common stock as contingent merger consideration and new, fully vested stock options by a Director and 10% owner suggests strong insider confidence in Klotho Neurosciences, Inc.'s future performance and valuation. This insider activity typically signals a belief that the stock is undervalued or has significant upside potential, making it a favorable indicator for potential investors.

Keywords

Klotho Neurosciences, KLTO, Samuel Zentman, insider trading, Form 4, beneficial ownership, stock options, contingent merger consideration, director, 10% owner